Eye injection of special cells may reduce corneal swelling

NCT ID NCT05636579

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests the safety of injecting special human cells (EO2002) into the eye to treat corneal swelling. Twelve adults with corneal edema from Fuchs' dystrophy or after cataract surgery will receive multiple injections, with or without Ripasudil eye drops. The main goal is to see if the treatment is safe and tolerable.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
EO2002 (magnetic human corneal endothelial cells) with or without Ripasudil eye drops
What this could lead to
If successful, this could point toward a new treatment for corneal swelling that might reduce the need for corneal transplants.
What could go wrong
This is a very early Phase 1 trial with only 12 people, so safety and effectiveness are not yet proven. The treatment involves injections into the eye, which carries risks like infection or inflammation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BULLOUS KERATOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Asociacion para Evitar la Ceguera en Mexico

    RECRUITING

    Mexico City, Mexico City, 04030, Mexico

More trials for these conditions

Other studies related to the condition(s) this trial covers.